A quest--halting the progression of autosomal dominant polycystic kidney disease.
From the Division of Nephrology and Hypertension, Oregon Health and Science University, Portland (D.H.E.).
David H
DH
Ellison
Julie R
JR
Ingelfinger
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000473:pathology*; D017706:Lisinopril / Q000627:therapeutic use*; D008297:Male; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy*; D000077333:Telmisartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D017706:Lisinopril; D000077333:Telmisartan